Text Size

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.

Garcia-Medina, J. J.; Benitez-Del-Castillo, J.; Rodríguez-Agirretxe, I.; Lopez-Lopez, F.; Moreno-Valladares, A.


  • 2022
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Hospital General Universitario Morales Meseguer, Murcia, Spain; Department of Ophthalmology, Hospital Universitario de Jerez, Jerez de la Frontera Cadiz, Spain; Department of Ophthalmology, Hospital Universitario Donostia, San Sebastian Guipuzcoa, Spain; Instituto Oftalmológico Gomez-Ulla, Santiago de Compostela Galicia, Spain; Department of Ophthalmology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain

Related Publications

Metabolomic Profiling of Open-Angle Glaucoma Etiologic Endotypes: Tohoku Multi-Omics Glaucoma Study

Hanyuda A.; Raita Y.; Ninomiya T.; Hashimoto K.; Takada N.; Sato K.; Inoue J.; Koshiba S.; Tamiya G.; Narita A.; Akiyama M.; Omodaka K.; Tsuda S.; Yokoyama Y.; Himori N.; Yamamoto Y.; Taniguchi T.; Negishi K.; Nakazawa T.


Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys

Yamamura K.; Mano H.; Fuwa M.; Ryoiwamura; Odani-Kawabata N.


Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial

Wang T.H.; Aung T.; Lu D.-W.; George R.; Senthil S.; Lu F.; Odani-Kawabata N.; Park K.H.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022